Role of DPR in Colorectal Cancer

Publication
Video
Special ReportsGastrointestinal Cancers: mCRC (Issue 9)
Volume 1
Issue 9

Volker Heinemann, MD, PhD, director of the Comprehensive Cancer Center at Ludwig Maximilian University of Munich, discusses how depth of response plays an important role in the treatment of colorectal cancer.

Articles in this issue
Phase III Study of Nintedanib Could Provide a New Option for mCRC, According to Expert
Phase III Study of Nintedanib Could Provide a New Option for mCRC, According to Expert
Role of DPR in Colorectal Cancer
Role of DPR in Colorectal Cancer
Overview of the Lume 1 and 2 Trials
Overview of the Lume 1 and 2 Trials
Impact of HER2 Amplification in Colorectal Cancer
Impact of HER2 Amplification in Colorectal Cancer
Tumor Location Findings Shed Light on CALGB/SWOG 80405, FIRE-3 Discrepancy
Tumor Location Findings Shed Light on CALGB/SWOG 80405, FIRE-3 Discrepancy
ctDNA Positivity Could Spell Higher Risk of Recurrence in Early-Stage Colon Cancer
ctDNA Positivity Could Spell Higher Risk of Recurrence in Early-Stage Colon Cancer
Novel Immunotherapy Combinations on Horizon for mCRC
Novel Immunotherapy Combinations on Horizon for mCRC
SIRT Added to First-line Chemo Improves Response in Colorectal Cancer
SIRT Added to First-line Chemo Improves Response in Colorectal Cancer
Recent Videos
Rohit Gosain, MD; Rahul Gosain, MD; and Pamela L. Kunz, MD, presenting slides
Rohit Gosain, MD; Rahul Gosain, MD; and Pamela L. Kunz, MD, presenting slides
Related Content
Invikafusp Alfa Shows Potential in PD-1 Refractory Solid Tumors

Invikafusp Alfa Shows Potential in PD-1 Refractory Solid Tumors

Jordyn Sava
November 21st 2024
Article

Invikafusp alfa showed promise as a treatment option across a range of high tumor mutational burden cancers or virally associated malignancies.

Read More

Behind the FDA Approval of Fruquintinib for Previously Treated mCRC

Behind the FDA Approval of Fruquintinib for Previously Treated mCRC

Jordyn Sava;Arvind Dasari, MD, MS
November 15th 2023
Podcast

In season 4, episode 18 of Targeted Talks, Arvind Dasari, MD, MS, dives into the recent approval of fruquintinib for patients with metastatic colorectal cancer.

Listen

Learning From a Multidisciplinary Approach in Graft-Vs-Host Disease

Learning From a Multidisciplinary Approach in Graft-Vs-Host Disease

Jonah Feldman
November 15th 2024
Article

In this feature, Memorial Sloan Kettering Cancer Center physicians explain what drives the collaborative process in their multidisciplinary graft-vs-host disease clinic.

Read More

Special Episode: Insight on Targeting Rare Genomic Alterations in Colorectal Cancers

Special Episode: Insight on Targeting Rare Genomic Alterations in Colorectal Cancers

Michael J. Overman, MD;Nichole Tucker
July 15th 2021
Podcast

In season 2, episode 6 of Targeted Talks, Dr. Michael J. Overman, joins Targeted Oncology for a special discussion around rare genomic alterations in colorectal cancer

Listen

Fellow's Perspective: Patient Case of Newly Diagnosed Multiple Myeloma

Fellow's Perspective: Patient Case of Newly Diagnosed Multiple Myeloma

Targeted Oncology Staff
November 13th 2024
Article

In a discussion with Peers & Perspectives in Oncology, fellowship program director Marc J. Braunstein, MD, PhD, FACP, and hematology/oncology fellow Olivia Main, MD, talk about their choices for a patient with transplant-eligible multiple myeloma and the data behind their decisions.

Read More

Nivolumab-Chemotherapy Combo Boosts PFS in cHL, Poised for Standard Use

Nivolumab-Chemotherapy Combo Boosts PFS in cHL, Poised for Standard Use

Morgan Bayer
November 12th 2024
Article

The N-AVD regimen showed improved progression-free survival and lower toxicity than BV-AVD in advanced Hodgkin lymphoma, particularly benefiting patients 60 and older.

Read More